A Pharmacogenomics Study of TAS-102
Phase 3
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-jRCT2080221873
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 266
Inclusion Criteria
Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum
Exclusion Criteria
- Has received TAS-102
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between the relative factor and disease control rate, overall survival, or progression-free survival<br>RECIST (ver.1.1)
- Secondary Outcome Measures
Name Time Method